Epica International, Inc. Announces U.S. FDA 510(k) Clearance for its Multi-modality, Mobile Computed Tomography Imaging Platform, SeeFactorCT3™
SAN CLEMENTE, Calif., Oct. 2, 2019 /PRNewswire/ -- Epica International, Inc. (Epica), received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its SeeFactorCT3™ Imaging Platform. SeeFactorCT3™ consists of 3 integrated imaging systems: CT, Fluoroscopy and Digital Radiography; a detachable patient table/chair, and sterile drape for interventional procedures. FDA clearance allows Epica to market these products in the United States.
The SeeFactorCT3™ is a diagnostic, interventional and intraoperative imaging platform that obtains ultra high-resolution 3D volumetric images plus, full featured Fluoroscopy and Digital Radiography. Unlike conventional CT systems, SeeFactorCT3™ provides non-interpolated (slice-less, 100% real) image data, delivering isotropic image resolution as fine as 0.1mm in both soft and hard tissue, lesion detection as small as 0.2mm and Epica's "Pulsed Technology" to significantly reduce the radiation dose received by the patient and healthcare professionals.
The SeeFactorCT3™ Computed Tomography platform utilizes dynamic flat panel sensor technology that acquires sequences of the head including the ear, nose and throat (ENT), dento-maxillofacial complex, teeth, mandible and jaw, temporo-mandibular joint (TMJ), other areas of human skull and neck with sections of upper cervical spine, and upper and lower extremities for use in diagnostic and intraoperative support. The SeeFactorCT3™ displays 2D and 3D images for each examined anatomical region. The imaging platform is operated and can be used by physicians, surgeons, dentists, imaging technologists and other legally qualified professionals. The system is lightweight, maneuverable through hallways, normal sized doors, and can facilitate converting an unused room into a cost-effective, multi-modality, diagnostic and therapeutic imaging room within an ambulatory/outpatient center (ASC), imaging center or ER/Trauma areas of a hospital. The ultra-high resolution SeeFactorCT3™ imaging platform can also be moved to the patient in ICU, ER/Trauma areas, imaging room or operating room.
Frank D. D'Amelio, CEO of Epica International, Inc., said, "I am very pleased to announce this major milestone event in Epica's history; our progression into the human medical space. What started five years ago as a multidisciplinary team of scientists, medical device engineers, robotics experts, and clinicians focused on improvement of CT imaging, led to the development of a robotically controlled, non- interpolated diagnostic and intraoperative imaging platform, capable of identifying anatomies as small as the vasculature of a hummingbird with less radiation dose and cost. I thank Epica's employees for their commitment to bringing this technology to the human medical market. Having obtained this FDA 510(k) clearance for our SeeFactorCT3™, we will now increase our development focus on our Medical Robot, the integration of our CT imaging platform with our surgical assist robotic arm."
About Epica International, Inc.
Epica International is a market and technology leader in advanced medical imaging and precision robotics in human, animal and industrial markets worldwide. Epica designs, develops and distributes proprietary advanced medical imaging platforms and progressive robotic systems that guide and assist users, ensure accuracy and strengthen outcomes. Epica has 75 issued and pending patents on its medical imaging and robotics platforms in the U.S., EU, and other countries. Epica International is headquartered in San Clemente, CA.
For further information on Epica International please visit our website at www.epicainternational.com.
For further information on this clearance and business development, please contact Daniel Naimey, Senior Vice President, Business Development & Corporate Marketing, Epica International, Inc., M:425.941.7365, [email protected]
SOURCE Epica International, Inc.
Share this article